|
|
||||||||
Regular Article |
Received August 10, 2001; revised November 11, December 4, 2001; accepted December 5, 2001. From the Division of Geriatrics and Neuropsychiatry, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA (RB,MG), the Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA (HD,MG), and the Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA (GPS). Address correspondence to Dr. Ganguli, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213-2593. e-mail: gangulim{at}msx.upmc.edu
OBJECTIVE: The authors sought to identify patterns and associations of prescription and over-the-counter sedative-hypnotic use in an older, rural, blue-collar, community-based cohort in southwestern Pennsylvania over 10 years. METHODS: A group of 1,627 individuals age 65 and over were recruited and assessed during 19871989 and re-assessed during approximately biennial waves. Data included sleep medications, demographics, depressive symptoms, sleep complaints, and cognitive functioning (Mini-Mental State Exam [MMSE]). RESULTS: At Waves 1 through 5, the mean age of the cohort increased from 73.4 to 80.5 years. Use of prescription sedative-hypnotics (primarily benzodiazepines) increased from 1.8% to 3.1%, and over-the-counter sedative-hypnotic use (primarily diphenhydramine) increased from 0.4% to 7.6%. At Wave 5 (19961998), 8.17% of the sample reported using diphenhydramine as a sleep aid. After adjusting for age and sex, diphenhydramine use was associated with higher education and more depressive symptoms, the latter becoming nonsignificant after controlling for initial insomnia. MMSE became significantly associated with diphenhydramine use when 143 subjects with dementia were excluded from the analysis. CONCLUSION: As the cohort aged, prescription sedative-hypnotic use remained relatively stable, whereas over-the-counter sedative use, principally diphenhydramine, increased substantially. The association of this drug with cognitive impairment in persons without dementia highlights its potential for causing adverse reactions in older adults.
Key Words: Cognition Diphenhydramine
This article has been cited by other articles:
![]() |
J. O. Brooks and J. C. Hoblyn Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults J Geriatr Psychiatry Neurol, December 1, 2007; 20(4): 199 - 214. [Abstract] [PDF] |
||||
![]() |
F. W. Unverzagt, Sujuan Gao, K. A. Lane, C. Callahan, A. Ogunniyi, O. Baiyewu, O. Gureje, K. S. Hall, and H. C. Hendrie Mild Cognitive Dysfunction: An Epidemiological Perspective With an Emphasis on African Americans J Geriatr Psychiatry Neurol, December 1, 2007; 20(4): 215 - 226. [Abstract] [PDF] |
||||
![]() |
R. D. Nebes, B. G. Pollock, E. M. Halligan, M. A. Kirshner, and P. R. Houck Serum Anticholinergic Activity and Motor Performance in Elderly Persons J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2007; 62(1): 83 - 85. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Steffens, E. Otey, G. S. Alexopoulos, M. A. Butters, B. Cuthbert, M. Ganguli, Y. E. Geda, H. C. Hendrie, R. R. Krishnan, A. Kumar, et al. Perspectives on Depression, Mild Cognitive Impairment, and Cognitive Decline Arch Gen Psychiatry, February 1, 2006; 63(2): 130 - 138. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ALL ISSUES | SEARCH | TABLE OF CONTENTS |